bi 836845
mAbexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01317420)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Insulin-like growth factor IINHIBITOR
IGF1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 836845
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02204072 | Phase 1 | Nov 11, 2014 | Boehringer Ingelheim |
| NCT02191891 | Phase 1 | Oct 21, 2014 | Boehringer Ingelheim |
| NCT02145741 | Phase 1 | Jun 1, 2014 | Boehringer Ingelheim |
| NCT02123823 | Phase 1 | May 1, 2014 | Boehringer Ingelheim |
| NCT01403974 | Phase 1 | Jul 1, 2011 | Boehringer Ingelheim |
| NCT01317420 | Phase 1 | Apr 1, 2011 | Boehringer Ingelheim |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 6 | 6 | 1 | 2011 |
1 organizations
Page 1 / 1